Cue Health's at-home molecular test bet: $2.3B IPO, then Chapter 7 wind-down in May 2024

Cue Health sold an app-connected, palm-sized molecular testing system — swab, cartridge and reusable reader that returned COVID-19 results in about 20 minutes and uploaded them to a mobile app.

That palm-sized molecular tests could take lab-quality COVID testing into homes and workplaces, and that pandemic-era demand would become a durable market.

About $235M from private investors before a $200M IPO at a $2.3B valuation (Mercom, 2021-09).

Cue Health was founded in 2010 to build an at-home flu test. When COVID-19 arrived, it won FDA authorization for a palm-sized molecular test, landed a $481 million US government contract in 2020, and agreed in April 2021 to supply test kits and readers to Google's US employees.

Revenue exploded from $5M in H1 2020 to $201.9M in H1 2021, with more than 80% coming from the public sector. Cue went public on Nasdaq in September 2021, raising $200M at a $2.3B valuation. After the pandemic peaked, demand collapsed, the company cut staff repeatedly and teetered on insolvency; in May 2024 the FDA warned consumers not to use Cue's only authorized COVID test kit.

On 2024-05-24 Cue laid off all remaining employees and shut down; on 2024-05-28 it filed voluntary Chapter 7 petitions in Delaware to wind down, with a bankruptcy trustee appointed to gather and sell its assets and pay creditors.

Cue bet that palm-sized molecular tests would take lab-quality diagnostics into homes and workplaces, with COVID as the wedge into a broader testing platform.

Its revenue was overwhelmingly tied to the pandemic — more than 80% from public-sector COVID demand — so the end of the emergency removed the foundation of the business.

After demand collapsed, the company could not find financing or a strategic buyer, and the FDA's May 2024 consumer warning on its only authorized product made a turnaround impossible.

The board concluded liquidation was the only option: all employees were let go on May 24, 2024, and Chapter 7 followed four days later.

A pandemic tailwind is a market, not a moat: Cue's revenue was over 80% public-sector COVID demand, so when the emergency ended the business ended — a $2.3B IPO to Chapter 7 in under three years.

As of September 2, 2026, Cue Health is being liquidated: operations shut down on May 24, 2024, and the company filed voluntary Chapter 7 petitions in the District of Delaware on May 28, 2024, announcing that a bankruptcy trustee would gather and sell its assets to pay creditors. The company that went public at a $2.3B valuation in September 2021 ended with its only FDA-authorized product under an FDA consumer warning, all staff laid off, and no financing or strategic transaction found after an extensive search.